Remicade Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The remicade market size has grown strongly in recent years. It will grow from $2.65 billion in 2025 to $2.8 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing prevalence of autoimmune disorders, wider clinical acceptance of biologics, expansion of hospital infusion centers, improved diagnosis of inflammatory diseases, growth in specialty pharmaceutical distribution.

The remicade market size is expected to see strong growth in the next few years. It will grow to $3.43 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing demand for biosimilar competition, rising investments in biologics manufacturing, expansion of home infusion care models, growing focus on personalized autoimmune therapies, advancements in monoclonal antibody development. Major trends in the forecast period include increasing use of tnf-alpha inhibitor therapies, rising adoption of biologic treatments for autoimmune diseases, growing preference for long-term disease control drugs, expansion of specialty infusion services, enhanced focus on patient-centered treatment outcomes.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the Remicade market in the future. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, tissues, or organs, treating them as foreign invaders. The rise in autoimmune diseases is attributed to a mix of genetic factors, environmental changes, greater exposure to pollutants, lifestyle choices, and enhanced diagnostic awareness. Remicade (infliximab) is used to manage these diseases by targeting and inhibiting tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine involved in conditions like rheumatoid arthritis, Crohn's disease, and ulcerative colitis. For example, in April 2025, GOV.UK, a UK-based public health agency, reported that in 2024, 17.9% of individuals aged 16 and over self-reported a long-term musculoskeletal (MSK) condition, with a higher incidence in females (20%) compared to males (15.6%). Therefore, the rising incidence of autoimmune diseases is a driving force behind the growth of the Remicade market.

Leading companies in the Remicade (infliximab) market are focusing on developing innovative solutions, such as subcutaneous formulations of biologic therapies, to meet the growing demand for improved patient convenience, better treatment adherence, and more time-efficient alternatives to traditional intravenous dosing. Subcutaneous biologics allow patients to self-administer maintenance doses at home, reducing the need for infusion-center visits and offering a more accessible option compared to conventional IV formulations. For example, in March 2024, Celltrion USA, Inc., a US-based biopharmaceutical company, launched Zymfentra (infliximab-dyyb), the first FDA-approved subcutaneous formulation of infliximab. Zymfentra is indicated as maintenance therapy for adults with moderate-to-severe active ulcerative colitis (UC) and Crohn’s disease (CD), which are part of inflammatory bowel disease (IBD). Approved for use after IV induction with an infliximab product, Zymfentra offers a convenient, self-administered alternative for long-term disease management.

In September 2024, Tharimmune Inc., a US-based biopharmaceutical company, acquired a global license from Intract Pharma for an undisclosed amount. This acquisition aims to develop an oral version of infliximab, which has traditionally been administered intravenously, thereby improving patient compliance and potentially lowering healthcare costs related to long-term intravenous therapy. Intract Pharma Ltd. is a UK-based provider of infliximab.

Major companies operating in the remicade market are Janssen Biotech Inc.

North America was the largest region in the remicade market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the remicade market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the remicade market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the remicade market by increasing costs related to imported monoclonal antibody manufacturing equipment, active pharmaceutical ingredients, cold-chain logistics, and sterile delivery systems. Hospitals and specialty clinics in North America and Europe are most affected due to biologics import dependency, while Asia-Pacific experiences supply chain cost pressures. These tariffs elevate therapy costs and influence reimbursement dynamics. However, they are also encouraging localized biologics production, regional biosimilar development, and strengthened domestic pharmaceutical manufacturing capabilities.

The remicade market research report is one of a series of new reports that provides remicade market statistics, including remicade industry global market size, regional shares, competitors with a remicade market share, detailed remicade market segments, market trends and opportunities, and any further data you may need to thrive in the remicade industry. This remicade market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Remicade (infliximab) is a biologic drug classified as a tumor necrosis factor-alpha (TNF-α) inhibitor. It is used to treat autoimmune disorders such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By blocking TNF-α, a protein that plays a key role in inflammation, Remicade helps alleviate symptoms, prevent disease progression, and enhance the quality of life.

The primary disease indications for Remicade include Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and plaque psoriasis. Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract that often results in symptoms like abdominal pain, severe diarrhea, weight loss, and fatigue. The medication can be administered via subcutaneous, intravenous, or parenteral routes, and is used in settings such as hospitals, clinics, ambulatory care, and home care.

The remicade market consists of sales of biosimilars of remicade, combination therapy products, administration tools, and packaging formats. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.